3BNC117-LS
3BNC117-LS is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
Clinical Trials (7)
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
3BNC117-LS First-in-Human Phase 1 Study
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7